Milton Packer, MD, is a distinguished scholar in cardiovascular science working out of Baylor University Medical Center in Dallas. The chair of the department of clinical sciences at the University of Texas Southwestern Medical School, Dr. Packer, recently gave an interview discussing the EMPEROR Reduced study results, sponsored by Boehringer Ingelheim in collaboration with Eli Lilly sought to investigate the safety and efficacy of empagliflozin versus placebo on top of guideline-directed medical therapy in patients with heart failure with reduced ejection fraction. Dr. Packer called the outcomes in EMPEROR Reduced “very striking.”
The Drug: Empagliflozin
This drug’s trade name is Jardiance and is used along with diet and exercise to treat type 2 diabetes. It was approved for medical use in the USA and in the EU by 2014. Recently, it was reported that the drug met its endpoint in the EMPEROR Reduced study to test whether it can risk heart failure with reduced ejection fraction in patients with and without diabetes.
The EMPEROR Reduced study started in March 2017 through Spring 2020.
According to an interview recently published and streamed by A...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).